Live updates

PiP breast implants 'not a health risk' despite high rupture rate

by - Consumer Editor

There was good news today for women who were given faulty breast implants filled with non-medical silicone.

A group of NHS experts said the gel inside the PiP Implants was not toxic or cancer-causing, and should not lead to long-term problems.

However, the bad news is that the implants are twice as likely to rupture as other brands.

BAAPS: Women should have the right to opt for PiP implants removal

Despite rigorous testing showing no long-term danger to human health from the individual chemicals in the gel, the fact remains that PIPs are significantly more likely to rupture and leak and, therefore, cause physical reactions in an unacceptable proportion of the patients.

We agree with the report findings that anxiety itself is a form of health risk and thus it is entirely reasonable for women to have the right to opt for removal - regardless of whether there has been rupture.

– The British Association of Aesthetic Plastic Surgeons


BAAPS: PiP implants should be removed due to proven ruptures

by - Consumer Editor

The report on PiP said the implants have high rupture rates, which the firm always denied.

Cosmetic surgeon group BAPPS said all implants should be removed due to the proven rupture rate. The official findings on breast implants confirms ITV News' findings broadcast in January.

The new report concentrates on the health aspects but campaigners also want a report into regulatory failings.


PIP patient: the NHS 'should not be sneering at us'

by - Consumer Editor

MPs agreed that women who had their PIP surgery privately should be able to have the implants removed on the NHS if there is clinical need. But they said the Department of Health should consider allowing these women to pay for new implants.

I spoke to Rebecca Thorne who had PIP implant surgery. She says women should not be made to pay twice.

'Inadequate' response to PIP scandal

A Commons Health Committee report said the communication from the government and the Medicines and Healthcare products Regulatory Agency was "inadequate".

The action taken to communicate with affected women after March 2010 was inadequate.

The Committee recognises that private clinics had a duty to contact their patients directly, but the Medicines and Healthcare products Regulatory Agency and the Department of Health also had a duty to raise public awareness."

– Commons Health Committee report
Load more updates


Today's top stories